Modelling transmission thresholds and hypoendemic stability for onchocerciasis elimination
- PMID: 40258021
- PMCID: PMC12052207
- DOI: 10.1371/journal.pcbi.1013026
Modelling transmission thresholds and hypoendemic stability for onchocerciasis elimination
Abstract
The World Health Organization (WHO) has proposed elimination of onchocerciasis transmission (EOT) in a third of endemic countries by 2030. This requires country-wide verification of EOT. Prior to the shift from morbidity control to EOT, interventions in Africa were mostly targeted at moderate- to high-transmission settings, where morbidity was most severe. Consequently, there remain numerous low transmission (hypoendemic) settings which have hitherto not received mass drug administration (MDA) with ivermectin. The WHO has prioritised the delineation of hypoendemic settings to ascertain treatment needs. However, the stability of transmission at such low levels remains poorly understood. We use the stochastic EPIONCHO-IBM transmission model to characterise the stability of transmission dynamics in hypoendemic settings and identify a range of threshold biting rates (TBRs, the annual vector biting rates below which transmission cannot be sustained). We show how TBRs are dependent on population size, inter-individual exposure heterogeneity and simulation time. In contrast with deterministic expectations, there is no fixed TBR; instead, transmission can persist between 70 and 300 bites/person/year. Using survivorship models on data generated from model simulations, we find that multiple vector biting rates can sustain hypoendemic prevalence for several decades. These findings challenge the assumption that hypoendemic foci would naturally fade out following treatment in nearby higher-endemicity regions. Our modelling suggests that, to achieve EOT, treatment should be extended to all areas where endogenous infection is identified, emphasising the need for improved diagnostic tools suitable for detecting low-prevalence infection and for strategies that allow safe treatment of communities where MDA would not be suitable.
Copyright: © 2025 Stapley et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures



Similar articles
-
How Can Onchocerciasis Elimination in Africa Be Accelerated? Modeling the Impact of Increased Ivermectin Treatment Frequency and Complementary Vector Control.Clin Infect Dis. 2018 Jun 1;66(suppl_4):S267-S274. doi: 10.1093/cid/cix1137. Clin Infect Dis. 2018. PMID: 29860291 Free PMC article.
-
Assessing Hypoendemic Onchocerciasis in Loa loa Endemic Areas of Southeast Nigeria.Am J Trop Med Hyg. 2020 Dec;103(6):2328-2335. doi: 10.4269/ajtmh.20-0368. Epub 2020 Sep 17. Am J Trop Med Hyg. 2020. PMID: 32959756 Free PMC article.
-
Does onchocerciasis transmission take place in hypoendemic areas? a study from the North Region of Cameroon.Trop Med Int Health. 2010 May;15(5):645-52. doi: 10.1111/j.1365-3156.2010.02501.x. Epub 2010 Mar 19. Trop Med Int Health. 2010. PMID: 20345553
-
Vector control and entomological capacity for onchocerciasis elimination.Trends Parasitol. 2022 Jul;38(7):591-604. doi: 10.1016/j.pt.2022.03.003. Epub 2022 Apr 1. Trends Parasitol. 2022. PMID: 35379556 Review.
-
Assessment and monitoring of onchocerciasis in Latin America.Adv Parasitol. 2011;77:175-226. doi: 10.1016/B978-0-12-391429-3.00008-3. Adv Parasitol. 2011. PMID: 22137585 Review.
References
-
- GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024;403(10440):2133–61. doi: 10.1016/S0140-6736(24)00757-8 - DOI - PMC - PubMed